| 000 | 01794cam a2200313 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223031749.0 | ||
| 008 | 170801s2015 ua do f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aGift | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.34.M.Sc.2015.He.N | ||
| 100 | 0 | _aHeba Ali Mohamed Shendy | |
| 245 | 1 | 2 |
_aA novel cohort study of Chr9p21 (desert gene) genetic variants in cardiovascular patients with type-2 diabetes / _cHeba Ali Mohamed Shendy ; Supervised Mohamed Z. Gad , Sally Ibrahim Hassanein |
| 260 |
_aCairo : _bHeba Ali Mohamed Shendy , _c2015 |
||
| 300 |
_a112 Leaves : _bcharts , photographs ; _c30cm |
||
| 502 | _aThesis (M.Sc.) - German University - Faculty of Postgraduate Studies and Scientific Research - Department of Biochemistry | ||
| 520 | _aCardiovascular disease is a leading cause of death worldwide. Chr9p21 locus happened to be the most robust genetic marker of CAD. The entire core of chr9p21 is covered by 'ANRIL' and lies in a region that is free from any coding proteins and therefore it is called the desert gene. Beside this region, are some protein coding genes, CDKN2A, CDKN2B. The association mechanisms for chr9p21 with atherosclerotic disease are vague but, it was suggested that ANRIL, influences the regulation of the epigenetic modification and thus modulate cardiovascular risk, as its expression is highly detected in vascular tissues related to atherosclerosis | ||
| 653 | 4 | _aCardiovascular patients | |
| 653 | 4 | _aChr9p21 | |
| 653 | 4 | _aType-2 diabetes | |
| 700 | 0 |
_aMohamed Z. Gad , _eSupervisor |
|
| 700 | 0 |
_aSally Ibrahim Hassanein , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c61754 _d61754 |
||